Andreas Mattsson
M. Sc., CSO and co-founder
Evaxion Biotech
Denmark
Biography
Andreas holds a Master of Science in engineering and bioinformatics from the Danish Technological University and is currently finishing his PhD. Prior to working at Evaxion, he has worked for six years for Novo Nordisk developing in silico platforms. Over the last five years Andreas has worked on developing Evaxion’s in silico platform including EDEN Technology. Andreas is currently developing new in silico technologies, which will enable cancer vaccine discovery, speed up the vaccine discovery and develop his capabilities.
Research Interest
silico technologies
